Founding Year: 2014
Waverley Pharma was founded in 2014 and became a public company in October 2017. The company trades under the symbol WAVE on the TSX Venture Exchange. As an oncology-focused pharma company, Waverley Pharma carefully monitors opportunities and possible acquisitions of related pharmaceutical products in order to realize long-term value.
Waverley Pharma Inc. is a specialty pharma company that is dedicated to the development and commercialization of safe, effective, and affordable therapeutics. The company’s current focus is on the generic oncology market in the United Kingdom (U.K.) and North America. The company has five generic oncology products on the U.K. market and is awaiting regulatory approval of four additional oncology generics for the U.K. and North American markets. The company currently has a pipeline of products in different stages of development, through multiple partnerships. Waverley Pharma is committed to providing patients with affordable prescription medicines that lower healthcare costs and provide a better quality of life.
Safe And Effective Oncology Drugs
WaverleyPharma is an emerging pharmaceutical company focused on the development and commercialization of safe, effective, and affordable cancer therapeutics in the EU, United Kingdom, and North American markets.
Waverley Pharma is working in collaboration with Reliance Life Sciences (RLS), part of a conglomerate based in Mumbai, India, for the commercialization of several oncology drugs for the United States and European markets.
Pharmaceuticals on the European Market:
· Erlotinib: Erlotinib is manufactured by RLS. Waverley Pharma has a binding contract with the U.K. National Health Service for the supply of Erlotinib.
· Temozolomide: Temozolomide is manufactured by RLS, and the binding contracts with the UK National Health Service for the supply of temozolomide have been transferred to Waverley Pharma.
· Capecitabine: Capecitabine is manufactured by RLS, and the binding contracts with the UK National Health Service for the supply of capecitabine have been transferred to Waverley Pharma. Waverley Pharma has exclusive rights for Germany and seeking a sales and marketing partner.
Waverly Pharma is committed to providing patients with affordable prescription medicines that lower healthcare costs and provide a better quality of life.
New Drug Discovery Program: PARP-1 Inhibitors
Cancer is a group of more than 200 diseases affecting different parts of the body. They all share one common characteristic; unchecked cell growth progressing towards unlimited expansion and requiring different approaches for its treatment. Both radiation therapy and chemotherapeutic drugs such as alkylating agents, anti-metabolites, and topoisomerase inhibitors are designed to damage DNA in order to prevent cancer cells from growing.
It is postulated that the effect of chemotherapy and radiation therapy is dampened by DNA repair enzymes 1 Poly (ADP-Ribose) Polymerase-1 (PARP-1) belongs to the PARP family of enzymes and is involved in the detection and repair of DNA damage. PARP-1 inhibitors are a new class of anticancer agents targeting DNA repair mechanisms. The inhibition of PARP-1 is of clinical importance in various types of cancer. PARP-1 inhibitors have shown great potential to target cancers such as high-grade ovarian cancers and triple-negative breast cancers which are resistant to current treatment. PARP-1 inhibitor can be used both as a monotherapy to selectively kill cancer cells and also in combination.
Acquisition Of Two Generic Oncology Products to Strengthen the Portfolio
Waverly Pharma’s wholly-owned subsidiary in Barbados, Waverly Pharma International Inc., has acquired two generic oncology products, temozolomide, and capecitabine, currently marketed in the United Kingdom, from Reliance Life Sciences Private Limited (“RLS”). The products were developed by RLS, and the binding contracts with the UK National Health Service for the supply of these products are being transferred to Waverly Pharma.
RLS will manufacture the two products for Waverley Pharma at its Medicines and Healthcare products Regulatory Agency-approved manufacturing facility in Mumbai, India. Waverly Pharma expects to make modest profit margins on the products after paying transfer prices to RLS, and after distributor and analytical testing charges in the UK are accounted for.
“While this acquisition transforms Waverley Pharma into a revenue-generating company, it, more importantly, positions us well for the launch of WAV-101 and 102, once they get approved in the European Union,” stated the Company’s President and CEO, Dr. George R. Thomas.
“Reliance Life Sciences is pleased to be able to contribute to strengthening the oncology product portfolio of Waverley Pharma with the addition of temozolomide and capecitabine, and, in the process, reinforce the relationship,” stated Mr. K.V. Subramaniam, President of RLS.
Meet the President and Chief Executive Officer
Larry Thiessen, MBA
Mr. Thiessen joined Waverley Pharma in February 2020. He has extensive pharmaceutical experience having worked for Bausch Health Companies Inc. (formerly Biovail Corporation), for 28 years, working his way up from manager to site director of the manufacturing operation in Steinbach, Manitoba. He led a team of roughly 400 employees and provided overall leadership and strategic direction at the operation. Mr. Thiessen has a Bachelor of Science in Biology and an Executive M.B.A. from Athabasca University in Edmonton, Alberta.
“Our mission is to develop and commercialize pharmaceuticals for safe and effective treatment.”